 |
SV Life Sciences Fund IISVLSF II closed in 1999 with total commitments of $280 million (plus $30 million of co-investments committed by partners and individuals affiliated with SVLS). As at 31 March 2010, the fund had invested $328 million (including re-investment) in 36 portfolio companies. To go to individual portfolio companies websites please click on company logo. Medical Devices / Instrumentation
AcuFocus: US
First investment: 2001 - Seed AcuFocus is based in Irvine, CA, AcuFocus is developing an implantable corneal in-lay for correction of presbyopia. 
Argonaut Technologies: US - Exited
First investment: 1999 - Expansion Argonaut developed a chemistry instrumentation for accelerated synthesis of novel organic molecules. Bought by Biotage after our exit. 
Cardiac Support Systems: US - Exited
First investment: 2000 - Seed Cardiac Support Systems was an innovation factory company. 
CardioFocus: US
First investment: 1999 - Early Stage CardioFocus is based in Marlborough, MA and has developed a catheter based approach using laser energy with visualization focused on atrial fibrillation. 
Cerebral Vascular Applications: US - Exited
First investment: 2000 - Seed Cerebral Vascular Applications incubated by TIF) developed a set of minimally invasive tools for atrial appendage sealing for stroke prevention. Licensed to Epitek. Funded through the innovation factory 
Confluent Surgical: US - Exited
First investment: 1999 - Early Stage Confluent Surgical was a biomaterials for adhesion prevention and vascular embolics. 
Insulet: US - Exited
First investment SVLSF II: 2001 - Start Up Insulet based in Bedford, MA, Insulet is designing and developing products that provide superior treatment for people with diabetes. The Company’s first commercial product is a wireless 3-day insulin pump. 
LipoSonix: US - Exited
First investment SVLSF II: 2001 - Seed First investment SVLSF III: 2003 - Seed LipoSonix based in Bothell, WA, was developing a product to use non-invasive, high intensity focused ultrasound to ablate unwanted subcutaneous cells as a non-invasive alternative to liposuction for body sculpting. Funded through the innovation factory. 
| |
